Yeltekin DEMİREL, Mustafa Haki SUCAKLI, Cem YENİCESU, Abdullah Sezai DOĞAN, Öztürk ÖZDEMİR

Hipertansif hastaların ailelerinde Apo E gen polimorfizmleri ve kan lipit profillerinin değerlendirilmesi

Amaç. Bu çalışmamızda, hipertansif hastaların ailelerinde Apo E gen polimorfizmleri ve kan lipitprofillerinin değerlendirilmesi amaçlanmıştır. Yöntem. Çalışmamız iki aşamada planlandı. İlkaşamada; 45 yaş altı popülasyonda CVD (CardiovascularDisease) gen mutasyonunudeğerlendirmek için, esansiyel hipertansiyona sahip 50 kişilik olgu grubu ve aynı yaş grubu vecinsiyette tansiyonu normal sınırlarda olan 50 kişilik kontrol grubu seçildi. Çalışmanın ikinciaşamasında, olgu grubundaki ACE gen polimorfizmi DD homozigot olan hastaların birinci dereceakrabalarında (50), genetik polimorfizm açısından değerlendirildi. Bulgular. Olgu grubundaApoE3/E4 alleline sahip olanların %88,9unda ailede hipertansiyon hikayesi mevcuidi. Aynışekilde E3/E2 genotipine sahip olanların hepsinde aile hikayesi pozitif idi. Olgu grubunda, 5 kişide(%10) ApoE E3/E2 gen polimorfizmi, 9 kişide (%18) ApoE E3/E4 gen polimorfizmi mevcuttu.Kontrol grubunda bu sayılar sırasıyla 7 ve 3 (%14 ve %6) idi. Olgu grubunda ApoE3/E2 genpolimorfizmi, kontrol grubundan daha yüksekti (p>0,05). Olgu grubunda E3/E4 genotipi, kontrolgrubundan yüksekti; ancak bu istatiksel olarak anlamlı bulunmadı. Total kolesterolü 200 mg/dL veüzeri olanların %62,5i olgu grubundaydı ve bu oran, kontrol grubuna göre (%37,5) istatistikselolarak anlamlı şekilde yüksekti (p

Assessment of Apo E gene polymorphism and blood lipid prof ile in f amilies ofpatients with hypertension

Aim. It is observed in studies that hypertension is a feature of familial and a variety of genepolymorphism is associated with hypertension. Method. This study was planned in two stages.Atthe first stage; to evaluate gene mutation, in population under the age of 45 CVD(CardiovascularDisease) case group of 50 persons with essential hypertension and at the same agegroup and sex, within normal blood pressure limits in a control group of 50 people was selected.Inthe second stage, cases of first-degree relatives of patients with homozygous polimorfizm DDACE gene group (parents and siblings) family group of 50 people, were evaluated for geneticpolymorphism. Results. Those with cases of allele ApoE3/E4 group, 88.9% had a family historyof hypertension. In the same way, in all of those with the E3/E2 genotype, family history waspositive. In the case group, 5 people (10%) E3/E2 ApoE gene polymorphism, 9 patients (18%) hadAPOE E3/E4 gene polymorphism. In the control group, these numbers was about respectively, 7,and 3 (14% and 6%).In the control group, ApoE3/E2 gene polymorphism, higher than controlgroup (p>0.05). Case group E3/E4 genotype, higher than the control group; but this difference wasnot statistically significant. Total cholesterol 200 mg/dL and above those 62.5% of people were inthe case group and this ratio compared to control group (37.5%) were significantly higher(p

PDF

___

1. Murray CJ, Lope AD. Evidence-based health policy-lessons from the global burden of disease study. Science 1996; 274: 740-3.
2. Joint national committee on detection. Evaluation and treatment of high blood pressure. The seventh report of the Joint national committe on prevention. Detection and treatment of high blood pressure (JNC VII). JAMA 2003; 289: 2560-74.
3. Guidelines Subcommittee of the World Health Organization: World Health Organization-International society of hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83.
4. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.
5. Altun B, Arıcı M, Nergizoglu G. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003. Journal of hypertension 2005; 23: 1817-23.
6. Onat A, Sansoy V, Yıldırım B. Erişkinlerimizde kan basıncı: 8-yıllık seyri, tedavi oranı, koroner kalp hastalığı ile bazı etkenlerle ilişkileri. Türk Kardiyoloji Derneği Arş 1999; 27: 136-43.
7. Sağlam K, Yılmaz Mİ, Sönmez A, Baykal Y. Primer Hipertansiyon 2003; 37.
8. Lascaux-Lefebvre V, Ruidavets J, Arveiler D. Influence of parental history of hypertension on blood pressure. J Hum Hypertens 1999; 13: 631-6.
9. Tozawa M, Oshiro S, Iseki C. Family history of hypertension and blood pressure in a screened cohort. Hypertens Res 2001; 24: 93-8.
10. Kikukawa N. Relationship between development of hypertension and a family history of high blood pressure in urban residents-analysis based on results of annual health examinations. Nippon Koshu Eisei Zasshi 2004; 51: 833-44.
11. Al-Safi SA, Aboul-Enein FH, Aboul-Enein BH, Manuel B. Influence of family history and lifestyle on blood pressure and heart rate in young adults in Jordan. Public Health 2006; 120: 1027-32.
12. Di Ruppo D, Farias, Guggisberg W, Delgado A. Family history as a risk factor for hypertension in adolescents. American Journal of Hypertension 2000; 13: 266.
13. Bedir A, Arık N, Adam B. Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. American Journal of Hypertension 1999; 12: 1038-43.
14. Maron DJ, Ridker PM, Pearson TA, Grundy S. Dislipidemi, Diğer Risk Faktörleri ve Koroner Kalp Hastalığının Önlenmesi: Fuster V. Alexander RW. ORourke RA: Hursts The Heart (10.baskı) McGraw-Hill 2002; 1131-60.
15. Halperin RO, Sesso HD, Ma J. Dyslipidemia and the risk of incident hypertension in men. Hypertension 2006; 47: 45-50.
16. Sesso HD, Buring JE, Chown MJ. A prospective study of plasma lipid levels and hypertension in women. Arch Intern Med 2005; 165: 2420-7.
17. Ağaçhan B, Yılmaz H, Öztürk O. Aterosklerozda Apolipoprotein E, Okside-LDL ve Lipid Profili İlişkisinin Araştırılması F. Ü. Sağlık Bil. Dergisi 2005; 19: 193-7.
18. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30.
19. Bhavani AB, Sastry KB, Reddy NK, Padma T. Lipid profile and apolipoprotein E polymorphism in essential hypertension. Indian Heart J 2005; 57: 151-7.
20. Imazu M, Yamamoto H, Toyofuku M et al. Association of apolipoprotein E phenotype with hypertension in Japanese-Americans: Data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 2001; 24: 523-9.
21. Lenzen HJ., Assman G, Buckwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low density lipoprotein cholesterol, and coronary artery disease. Clin Chem 1986; 32/5: 778-81.
22. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ: Factor XIII Val34Leu. A novel association with primary intracerebral hemorrhage. Stroke 1998; 29: 813-6.
23. Franco RF, Pazin-Filho A, Tavella MH, Simões MV, Marin-Neto JA, Zago MA.Factor XIII val34leu and the risk of myocardial infarction. Haematologica 2000; 85: 67-71.
24. Braeckman L, De Bacquer D, Rosseneu M, De Bacquer G. Apolipoprotein E polymorphism in middle-aged Belgian men: Phenotype distribution and relation to serum lipids and lipoproteins. Atherosclerosis 1996; 120: 67-73.
25. Davignon J, Greeg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 1988; 8: 1-21.
26. Hixson JE. Pathological Determinants of Atherosclerosis in Youth (PDAY) Research Group: Apolipoprotein E polymorphism affect atherosclerosis in young males. Arterioscler Thromb 1991; 11: 1237-44.
27. Jemaa R, Elasmi M, Naouali C. Apolipoprotein E polymorphism in the Tunisian population: Frequency and effect on lipid parameters. Clin Biochem 2006; 39: 816-20.
28. Yilmaz H, Isbir T, Ağaçhan B, Aydin M. Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct 2001; 19: 191-5.
29. Catto AJ, Kohler HP, Coore J, Mansfiel MW, Stickland MH, Grant PJ: Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93: 906-8.